Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07772921 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

StatusNot Yet Recruiting
PhasePhase 3
SponsorPfizer
Started2026-08-24
View on ClinicalTrials.gov ↗
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.
Trial Details
NCT Number NCT07772921
Lead Sponsor Pfizer
Conditions Asthma
Enrollment 1,100 participants
Start Date 2026-08-24
Primary Completion 2029-06-12 (estimated)
Study Completion 2029-09-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-19